← All indications
Autistic Disorder
A disorder beginning in childhood. It is marked by the presence of markedly abnormal or impaired development in social interaction and communication and a markedly restricted repertoire of activity and interest. Manifestations of the disorder vary greatly depending on the developmental level and chronological age of the individual. (DSM-V)
Drugs by status
Approved for this indication (5)
Phase 4 trials (13)
Phase 3 trials (20)
Phase 2 trials (33)
- oxytocin
- Nabiximols
- lenalidomide
- citalopram
- diphenhydramine
- ampalex
- succimer
- suvorexant
- folic acid
- ziprasidone
- icosapent ethyl
- l1-79
- levocarnitine
- quinidine
- riluzole
- sirolimus
- cannabis
- stem cells
- everolimus
- zolpidem
- allogeneic adipose derived mesenchymal stem cell
- allogeneic cord blood
- autologous umbilical cord blood
- umbilical cord mesenchymal stem cells
- cord blood hematopoietic stem cell
- trichuris suis ova
- multivitamins
- vasopressin
- dextromethorphan
- esomeprazole
- +3 more
Phase 1 trials (17)
Organizations
Organization Involved with Phase 4 Indications (34)
- Shire
- Bristol-Myers Squibb
- Bio Products Laboratory
- Forest Laboratories
- Eli Lilly
- Pfizer
- Isaac Melamed
- IRCCS Fondazione Stella Maris
- National Institute of Mental Health (NIMH)
- Samsung Medical Center
- University of Pittsburgh
- Harvard University
- Duke University
- University of Washington
- JPM van Stralen Medicine Professional
- Katholieke Universiteit Leuven
- Ohio State University
- University of Rochester
- University of South Carolina
- Tel Aviv University
- Medical University of South Carolina
- Icahn School of Medicine at Mount Sinai
- IMMUNOe
- University of North Carolina at Chapel Hill
- Vita-Salute University of Milano. Italy
- Ben Gurion University
- Massachusetts Institute of Technology
- Istituto di Fisiologia Clinica CNR
- Sungkyunkwan University
- The Israeli Society of Clinical Pediatrics
- +4 more
Organization Involved with Phase 3 Indications (48)
- Biomarin
- Servier
- Roche
- Curemark
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- Neuropharm
- Seaside Therapeutics, Inc.
- Sunovion
- Nobel Pharmaceuticals
- Repligen Corporation
- National Institutes of Health (NIH)
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institute on Deafness and Other Communication Disorders (NIDCD)
- Drexel University
- Emory University
- Indiana University
- Mclean Hospital
- Rutgers University
- University of Medicine and Dentistry of New Jersey
- University of Oklahoma
- University of Toronto
- Utrecht University
- University of Alberta
- University of Arkansas
- Wayne State University
- Yale University
- Columbia University
- Kurume University
- The Children's Health Council
- University of California, Davis
- +18 more
Organization Involved with Phase 2 Indications (75)
- Bioelectron
- Immunotec Inc.
- Merz
- OptiNose AS
- PediaMed Pharmaceuticals
- RespireRx
- The EMMES Corporation
- Translational Biosciences
- FRAXA Research Foundation
- Sutter Medical Foundation
- Yamo Pharmaceuticals LLC
- Children's Hospital of Philadelphia
- University of Pennsylvania
- University of Arizona
- Ain Shams University
- Arizona State University
- Boston University
- Guangzhou Medical University
- Hamamatsu University
- Hoosier Cancer Research Network
- Johns Hopkins University
- Los Angeles Biomedical Research Institute
- McMaster University
- Minia University
- Multidisciplinary Association for Psychedelic Studies
- Northwestern University
- Nova Southeastern University
- Oregon Health and Science University
- Osaka University
- Southwest College of Naturopathic Medicine
- +45 more
Organization Involved with Phase 1 Indications (19)
- Allergan
- Institute for Neurodegenerative Disorders
- University of Reading
- Instituto de Psiquiatria
- University of Toulouse
- University of Missouri
- Pennsylvania State University
- Clinical Research Associates, Inc.
- Thrasher Research Fund
- Clasado Biosciences
- Roivant Sciences, Inc.
- Cures Within Reach
- Perkin Elmer Inc.
- Fundatia Bio-Forum
- Children's Hospital Los Angeles
- Spitalul Angiomedica
- ProgenaBiome
- Ventura Clinical Trials
- Sun Genomics
Organization Involved with Other Experimental Indications (28)
- Cumberland Pharmaceuticals
- DSM
- National Center for Complementary and Integrative Health (NCCIH)
- Central South University
- University of London
- Loma Linda University
- McGill University
- Norton Healthcare
- The Center for Autism and Related Disorders
- University of Messina
- University of Regensburg
- University of Salerno
- University of Bari
- University of Zurich
- Mayo Clinic
- University of California, Berkeley
- University of Vienna
- University of Freiburg
- Trinity College Dublin
- Sun Yat-Sen University
- Washington University in St. Louis
- Organization for Autism Research
- Thoughtful House
- University of Novi Sad
- Franklin Institute of Wellness
- University of Coimbra
- Associazione Italiana Sindrome di Phelan-McDermid (AISPHEM)
- Mackay Medical College